安罗替尼耐药性与敏感性相关研究进展

Research Progress of Anlotinib’s Drug Resistance and Sensitivity

安罗替尼是由中国自主研发的新型抗肿瘤小分子药物,其在多种肿瘤的临床试验中都取得了良好的疗效。在化疗过程中,耐药性和敏感性直接关系到药物对肿瘤治疗的成败。肿瘤基因的表达水平在安罗替尼的选择下产生变化,进而引起信号通路的改变使肿瘤产生耐药性。而抑制与安罗替尼耐药机制相关的基因或合用其他抗肿瘤药物可以提高肿瘤对安罗替尼的敏感性。本文总结了体外安罗替尼的耐药性和敏感性机制的相关研究,并回顾了安罗替尼联用PD-1/PD-L1抑制剂逆转安罗替尼耐药性的临床报道,以期为安罗替尼的耐药性机制研究和临床用药提供参考。

Anlotinib is a new anti-tumor small-molecule drug independently developed by China,which has achieved good curative effect in the clinical trials of a variety of tumors.During chemotherapy,drug resistance and sensitivity are directly related to the success or failure of the tumor’s drug treatment.The expression level of the tumor genes changes under the selection of anlotinib,which then causes changes in the signaling pathways to induce the tumor’s drug resistance.While the inhibition of the genes associated with the mechanisms of anlotinib resistance or the combination of other antitumor agents can improve the tumor’s sensitivity to anlotinib.This article summarizes the relevant studies on the resistance and sensitivity mechanism of anlotinib in vitro,and reviews the clinical reports of anlotinib in combination with PD-1/PD-L1 inhibitors to reverse anlotinib resistance,in order to provide a reference for the study of anlotinib resistance mechanism and clinical application.